

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1-10 (Canceled)

11. (new) A vaccine for Epstein Barr Virus (EBV) comprising gp350 protein, wherein the gp350 protein contains a deletion in both the membrane spanning region and the C-terminus, and wherein the vaccine is substantially free from gp220 protein.

12. (new) A vaccine for Epstein Barr Virus (EBV) comprising a homogenous EBV gp350 protein encoded by a DNA sequence comprising a deletion in the membrane spanning region and a nonfunctional splice-site so that EBV gp350 is expressed as a fusion of an extracellular domain and a cytoplasmic domain in a soluble form and in the absence of EBV gp220.

13. (new) A vaccine for Epstein Barr Virus (EBV) comprising a homogenous EBV gp350 protein encoded by a DNA sequence encoding EBV gp350 protein or a shortened version of EBV gp350, wherein the EBV gp350 protein:

(i) has a deletion in the membrane spanning region resulting in a secreted product;

(ii) has a deletion of the membrane spanning region and the remaining C terminus;

(iii) has a deletion in the membrane spanning region and a deletion of the signal sequence;

(iv) has a deletion of the membrane spanning region and the remaining C terminus and a deletion of the signal sequence; or

(v) has a deletion of the signal sequence;

wherein said DNA sequence has a mutation at one or more splice sites preventing formation of gp220 mRNA transcript.

14. (new) The vaccine of claim 11, 12 or 13, wherein the vaccine is in admixture with a pharmaceutically acceptable carrier.

15. (new) The vaccine of claim 11, 12 or 13, wherein the deletion in the membrane spanning region comprises amino acids 863 to 907 of SEQ ID No. 18.

16. (new) The vaccine of claim 11 or 13, wherein the gp350 protein comprises amino acids 19 to 862 of SEQ ID No. 18.

17. (new) The vaccine of claim 11 or 13 wherein the gp350 protein comprises amino acids 1-862 of SEQ ID No. 18.

18. (new) The vaccine of claim 13, wherein the mutation in the donor splice site is from AAGT to GTCA and/or wherein the mutation in the acceptor splice site is from AGGT to TGGA.

19. (new) A method of treating an EBV-related disease or condition in a subject, comprising administering to the subject a gp350 protein, wherein the gp350 protein contains a deletion in both the membrane spanning region and the C-terminus, and wherein the vaccine is substantially free from gp220 protein.

20. (new) A method of treating an EBV-related disease or condition in a subject, comprising administering to the subject a homogenous EBV gp350 protein encoded by a DNA sequence comprising a deletion in the membrane spanning region and a nonfunctional splice-site so that EBV gp350 is expressed as a fusion of an extracellular domain and a cytoplasmic domain in a soluble form and in the absence of EBV gp220.

21. (new) A method of treating an EBV-related disease or condition in a subject, comprising administering to the subject a homogenous EBV gp350 protein encoded by a DNA sequence encoding EBV gp350 protein or a shortened version of EBV gp350 wherein the EBV gp350 protein:

(i) has a deletion in the membrane spanning region resulting in a secreted product;

(ii) has a deletion of the membrane spanning region and the remaining C terminus;

(iii) has a deletion in the membrane spanning region and a deletion of the signal sequence;

(iv) has a deletion of the membrane spanning region and the remaining C terminus and a deletion of the signal sequence; or

(v) has a deletion of the signal sequence;

wherein said DNA sequence has a mutation at one or more splice sites preventing formation of gp220 mRNA transcript.

22. (new) The method of claim 18, 19 or 20, wherein the vaccine is in admixture with a pharmaceutically acceptable carrier.

23. (new) The method of claim 18, 19 or 20, wherein the deletion in the membrane spanning region comprises amino acids 863 to 907 of SEQ ID No. 18.

24. (new) The method of claim 18, or 20, wherein the gp350 protein comprises amino acids 19 to 862 of SEQ ID No. 18.

25. (new) The method of claim 18, or 20, wherein the gp350 protein comprises amino acids 1-862 of SEQ ID No. 18.

26. (new) The method of claim 21, wherein the mutation in the donor splice site is from AAGT to GTCA and/or wherein the mutation in the acceptor splice site is from AGGT to TGGA.